Maharashtra, India

Sumanta Garai

This inventor holds 1 USPTO granted patent. Top assignee: Council of Scientific and Industrial Research. Active years: 2016.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Sumanta Garai

Introduction

Sumanta Garai is a notable inventor based in Maharashtra, India. He has made significant contributions to the field of chemistry, particularly in the area of asymmetric synthesis. His work has implications for the development of pharmaceuticals, showcasing the importance of innovation in scientific research.

Latest Patents

One of Sumanta Garai's key patents is titled "Asymmetric synthesis of (−)-venlafaxine using organocatalyst." This patent discloses a novel method for synthesizing (−)-venlafaxine through an organocatalytic process. The approach employs a unified strategy that includes organocatalytic Michael addition, regio-selective dehydration, and selective epoxide ring opening. This innovative method enhances the efficiency and effectiveness of the synthesis process.

Career Highlights

Sumanta Garai is affiliated with the Council of Scientific and Industrial Research, where he continues to contribute to scientific advancements. His work is characterized by a commitment to exploring new methodologies in chemical synthesis, which has garnered attention in the scientific community.

Collaborations

Throughout his career, Sumanta has collaborated with esteemed colleagues, including Subhash Prataprao Chavan and Kailash Pralhad Pawar. These collaborations have further enriched his research and expanded the impact of his innovations.

Conclusion

Sumanta Garai's contributions to the field of asymmetric synthesis exemplify the vital role of inventors in advancing scientific knowledge. His innovative approaches and collaborations highlight the importance of teamwork in achieving groundbreaking results.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…